Somatotropic axis dysfunction in non-alcoholic fatty liver disease: Beneficial hepatic and systemic effects of hormone supplementation
Cargando...
Archivos
Fecha
2018-05
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
MDPI AG
Nombre de Curso
Licencia CC
Licencia CC
Resumen
Background: Somatotropic axis dysfunction associated with non-alcoholic fatty liver disease (NAFLD) has potential multisystemic detrimental effects. Here, we analysed the effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) supplementation on liver histology, adipokine profile and muscle function in an NAFLD model. Methods: C57BL/6 mice were fed with a high fat diet (HFD) for 12 weeks and were separated into three groups treated for 4 weeks with: (1) High fat diet (HFD) (n = 10); (2) HFD + GH 9 μg/g/d (n = 10); (3) HFD + IGF-1 0.02 μg/g/d (n = 9). A control group fed a chow diet was included (n = 6). Liver histology, liver triglycerides content, serum alanine aminotransferase (ALT) activity, adiponectin and leptin serum levels, in vivo muscle strength, tetanic force and muscle fibre cross-sectional area (CSA) were measured. Results: HFD + GH and HFD + IGF-1 groups showed significantly lower ALT activity compared to HFD (p < 0.01). Liver triglyceride content in HFD + GH was decreased compared to HFD (p < 0.01). Histologic steatosis score was increased in HFD and HFD + GH group (p < 0.01), whereas HFD + IGF-1 presented no difference compared to the chow group (p = 0.3). HFD + GH group presented lower serum leptin and adiponectin levels compared to HFD. GH and IGF-1 supplementation therapy reverted HFD-induced reduction in muscle strength and CSA (sarcopenia). Conclusions: GH and IGF-1 supplementation induced significant improvement in liver steatosis, aminotransferases and sarcopenia in a diet-induced NAFLD model. © 2018 by the authors. Licensee MDPI, Basel, Switzerland.
Notas
Indexación: Scopus.
Acknowledgments: This work was financed by the project FONDECYT #1150311 a F.B.; #11171001 to D.C.; #1150327 to M.A. and #1161646 to C.C.; Comisión Nacional de Investigación Científica y Tecnologica (grant CONICYT PIA/Basal PFB12, Basal Centre for Excellence in Science and Technology to M.A.; Millennium Institute on Immunology and Immunotherapy [P09-016-F], Programa de Cooperación Internacional ECOS-Conicyt [C16S02], UNAB-DI [741-15/N] to C.C. Open access costs were covered by FONDECYT #1150311 a F.B.
Acknowledgments: This work was financed by the project FONDECYT #1150311 a F.B.; #11171001 to D.C.; #1150327 to M.A. and #1161646 to C.C.; Comisión Nacional de Investigación Científica y Tecnologica (grant CONICYT PIA/Basal PFB12, Basal Centre for Excellence in Science and Technology to M.A.; Millennium Institute on Immunology and Immunotherapy [P09-016-F], Programa de Cooperación Internacional ECOS-Conicyt [C16S02], UNAB-DI [741-15/N] to C.C. Open access costs were covered by FONDECYT #1150311 a F.B.
Palabras clave
Fatty liver, Growth hormone, IGF-1, Insulin growth factor 1, Somatotropic axis
Citación
International Journal of Molecular Sciences, 19(5), art. no. 1339